European Transcatheter Aortic Valve Implantation (TAVI) Market 2017: Essential Information about Reimbursement and National Funding for TAVI - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Transcatheter Aortic Valve Implantation (TAVI) in Europe" report to their offering.

This report presents a summary of the reimbursement situation in Europe for transcatheter aortic valve implantation (TAVI) for aortic stenosis. Use of both transfemoral and transapical TAVI is reviewed.

TAVI is a well established technology with reimbursement available in all studied European countries. The main payment models are diagnosis-related group (DRG) for entire hospitalization, add-on reimbursement (England, France, Italy in some regions) and fee for procedure and material (Belgium). All countries, except Italy, have specific procedure codes for TAVI. Brand-specific reimbursement is only available in Belgium and France, while in other countries reimbursement is established for the class of devices.

Reimbursement differs for different types of access for procedures only in France, Germany and Switzerland. In Germany and Switzerland procedures with transapical access has higher reimbursement.

Complications or strokes specifically do not impact allocation to DRG and reimbursement levels in any of the studied countries, with the exception of France.

Almost every country has implemented certain restrictions to provision of TAVI, which are limited to inoperable or operable patients at high surgical risk in the majority of studied countries.

Key Topics Covered:

1. Introduction and summary

2. Executive summary table

3. Methodology

4. Reimbursement analysis in Austria

5. Reimbursement analysis in Belgium

6. Reimbursement analysis in Denmark

7. Reimbursement analysis in England

8. Reimbursement analysis in France

9. Reimbursement analysis in Germany

10. Reimbursement analysis in Italy

11. Reimbursement analysis in the Netherlands

12. Reimbursement analysis in Norway

13. Reimbursement analysis in Sweden

14. Reimbursement analysis in Switzerland

Companies Mentioned

  • Abbott (previously - St. Jude Medical) (Portico)
  • Boston Scientific (Lotus)
  • Colibri Heart Valve
  • Direct Flow Medical
  • Edwards Lifesciences (Sapien)
  • JenaValve
  • Medtronic (CoreValve)
  • Symetis
  • Transcatheter Technologies

For more information about this report visit http://www.researchandmarkets.com/research/7csg4c/transcatheter

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Cardiovascular Devices

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Cardiovascular Devices